BioLife Solutions Q3 revenue up 30% to $30.6M; raises Cell Processing guidance to $72-73M

BIOLIFE SOLUTIONS INC

2024-Q3 EPS reported -$0.71 revenue$85,678,000

Q3 revenue $30.6M (+30% YoY); Cell Processing $19.0M (+43% YoY); adjusted EBITDA $6.1M (20% margin).
GAAP net loss from continuing ops $1.7M vs $15.8M YoY; adj. gross margin 54% (up from 44%).
Completed sale of SciSafe biostorage business for $73M cash on Nov 12, 2024.
FY2024 revenue guidance revised to $98-100M; Cell Processing raised to $72-73M (previously $70-71M).
Biostorage guidance cut to $26-27M due to SciSafe divestiture; management expects positive adjusted EBITDA for full year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.